ArticleGynecologic oncology2019
Genes associated with bowel metastases in ovarian cancer.
Article in Gynecologic oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 60 citations in OpenAlex.
- Impact of Anatomical Site on RNA-Based Molecular Subtypes in Paired High-Grade Serous Ovarian Carcinoma Samples.Cancers · 2026Article
- LRRC15-CAR T Cells for the Treatment of Osteosarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Periostin: A matricellular protein with a multifaceted role in tumorigenesis (Review).International journal of molecular medicine · 2025Review
- Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance.Signal transduction and targeted therapy · 2025Article
- Article
- Automated sparse feature selection in high-dimensional proteomics data via 1-bit compressed sensing and K-Medoids clustering.BMC bioinformatics · 2025Article
- Relationship Between Thyroid Dysfunction and Ovarian Cancer.Biomolecules · 2025Review
- CAPRIN1 Transcriptionally Activated PLPP4 to Inhibit DOX Sensitivity and Promote Breast Cancer Progression.Cell biochemistry and biophysics · 2025Article
- The thyroid hormone activating enzyme, DIO2, is a potential pan-cancer biomarker and immunotherapy target.Journal of endocrinological investigation · 2025Article
- Article
- The role of LRRC15-SCG5 in ECM protein binding as a prognostic signature for urothelial carcinoma.American journal of cancer research · 2025Article
- Assessing the role of LRRCl5 as a prognostic and therapeutic biomarker in glioblastoma.American journal of translational research · 2025Article
- Clonal tracking in cancer and metastasis.Cancer metastasis reviews · 2024Review
- AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication.British journal of cancer · 2024Article
- BAY-9835: Discovery of the First Orally Bioavailable ADAMTS7 Inhibitor.Journal of medicinal chemistry · 2024Article
- Effects of metalloprotease ADAMTS12 on cervical cancer cell phenotype and its potential mechanism.Discover oncology · 2023Article
- LRRC15 expression indicates high level of stemness regulated by TWIST1 in mesenchymal stem cells.iScience · 2023Article
- LRRC superfamily expression in stromal cells predicts the clinical prognosis and platinum resistance of ovarian cancer.BMC medical genomics · 2023Article
- DNA barcoded competitive clone-initiating cell analysis reveals novel features of metastatic growth in a cancer xenograft model.NAR cancer · 2022Article
- Exploiting LRRC15 as a Novel Therapeutic Target in Cancer.Cancer research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThis study is designed to identify genes and pathways that could promote metastasis to the bowel in high-grade serous ovarian cancer (OC) and evaluate their associations with clinical outcomes.
methodsWe performed RNA sequencing of OC primary tumors (PTs) and their corresponding bowel metastases (n = 21 discovery set; n = 18 replication set). Differentially expressed genes (DEGs) were those expressed at least 2-fold higher in bowel metastases (BMets) than PTs in at least 30% of patients (P < .05) with no increased expression in paired benign bowel tissue and were validated with quantitative reverse transcription PCR. Using an independent OC cohort (n = 333), associations between DEGs in PTs and surgical and clinical outcomes were performed. Immunohistochemistry and mouse xenograft studies were performed to confirm the role of LRRC15 in promoting metastasis.
resultsAmong 27 DEGs in the discovery set, 21 were confirmed in the replication set: SFRP2, Col11A1, LRRC15, ADAM12, ADAMTS12, MFAP5, LUM, PLPP4, FAP, POSTN, GRP, MMP11, MMP13, C1QTNF3, EPYC, DIO2, KCNA1, NETO1, NTM, MYH13, and PVALB. Higher expression of more than half of the genes in the PT was associated with an increased requirement for bowel resection at primary surgery and an inability to achieve complete cytoreduction. Increased expression of LRRC15 in BMets was confirmed by immunohistochemistry and knockdown of LRRC15 significantly inhibited tumor progression in mice.
conclusionsWe identified 21 genes that are overexpressed in bowel metastases among patients with OC. Our findings will help select potential molecular targets for the prevention and treatment of malignant bowel obstruction in OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.